Liwanli Innovation Co (TPE:3054) Operating Margin %: -188.71% (As of Dec. 2025)


TPE:3054 Liwanli Innovation Co Ltd TPE:3054
61 GF Score
Price NT$62.80
GF Value NT$39.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Liwanli Innovation Co Operating Margin %?

Liwanli Innovation Co TPE:3054 +0.16% 61 Operating Margin % is -188.71% as of Dec. 2025. GuruFocus rates TPE:3054 with a GF Score™ of 61/100 and a GF Value™ of NT$39.71 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Liwanli Innovation Co ranks worse than 89.6% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Liwanli Innovation Co's Operating Income for the three months ended in Dec. 2025 was NT$-45.1 Mil. Liwanli Innovation Co's Revenue for the three months ended in Dec. 2025 was NT$23.9 Mil. Therefore, Liwanli Innovation Co's Operating Margin % for the quarter that ended in Dec. 2025 was -188.71%.

Good Sign:

Liwanli Innovation Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Liwanli Innovation Co's Operating Margin % or its related term are showing as below:

TPE:3054' s Operating Margin % Range Over the Past 10 Years
Min: -118.12   Med: -48   Max: -6.78
Current: -57.11


TPE:3054's Operating Margin % is ranked worse than
89.6% of 952 companies
in the Drug Manufacturers industry
Industry Median: 7.58 vs TPE:3054: -57.11

Liwanli Innovation Co's 5-Year Average Operating Margin % Growth Rate was 3.40% per year.

Liwanli Innovation Co's Operating Income for the three months ended in Dec. 2025 was NT$-45.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-71.7 Mil.


Liwanli Innovation Co  (TPE:3054) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Liwanli Innovation Co Operating Margin % Related Terms


Liwanli Innovation Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Liwanli Innovation Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liwanli Innovation Co Operating Margin % Chart

Liwanli Innovation Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -101.72 -118.12 -98.53 -38.11 -57.11

Liwanli Innovation Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.56 -56.55 -21.82 -18.09 -188.71

TPE:3054 vs ZTS, UTHR: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liwanli Innovation Co Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Liwanli Innovation Co's Operating Margin % falls into.


TPE:3054
61GF Score
Liwanli Innovation Co Ltd TPE:3054
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liwanli Innovation Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Liwanli Innovation Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-71.699 / 125.54
=-57.11 %

Liwanli Innovation Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-45.098 / 23.898
=-188.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -188.71% mean?
Liwanli Innovation Co (TPE:3054) has a Operating Margin % of -188.71% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Liwanli Innovation Co and its competitors. According to the industry distribution chart, Liwanli Innovation Co ranks #853 out of 952 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Liwanli Innovation Co's Operating Margin % too high?
Liwanli Innovation Co's current Operating Margin % is -188.71%. Based on the distribution chart, Liwanli Innovation Co ranks #853 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #853 out of 952 companies for Operating Margin %. This places Liwanli Innovation Co in the lower half of its industry. The industry median Operating Margin % is 7.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current Operating Margin % is -188.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.71, compared to a current price of NT$62.80 — trading 58.1% above its estimated fair value. The current Operating Margin % is -188.71%. Liwanli Innovation Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current Operating Margin % is -188.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?

Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued. The current stock price of NT$62.80 is trading 58.1% above its estimated GF Value™ of NT$39.71. GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.

Key valuation signals for TPE:3054:

  • Operating Margin %: -188.71%
  • GF Value™: NT$39.71 vs. price of NT$62.80 (58.1% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Liwanli Innovation Co Business Description

Address No. 537, Tanmei Street, 9th Floor, Neihu District, Taipei City, TWN, 235
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
61GF Score

Get the complete analysis for TPE:3054

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$62.80
Price
NT$39.71
GF Value